Please Wait a Moment
X

Articles

22Apr

Update on CTS Implementation of the Grifols Procleix Ultrio Elite Assay

22 Apr, 2020 | Return|

In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV, and HCV), performed on the Tigris testing platform, to the newer Ultrio Elite triplex assay, and performed on the Panther testing platform. The CTS Phoenix lab will implement first on July 7th, with the 4 remaining CTS labs located in Charlotte, Dallas, St. Louis amd Tampa all implementing on July 13, 2020.

 

Click here for all the details: Communications

Related

Shipping conditions for Monolisa anti-HBs EIA

After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...

Read More >

Updated Sample Acceptability Document

CTS was recently notified that one of the tubes listed in the Sample Acceptability document...

Read More >

Convalescent Plasma Testing for COVID-19

CTS Tampa has implemented the Ortho Vitros Anti-SARS-CoV-2 Total test which qualitatively detects an...

Read More >

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- 1st Update

This is the first update to the original CTS communication distributed on July 6th. As previously co...

Read More >

CTS conversion to the Ortho VERSEIA Integrated Processor (VIP) in January 2021

After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...

Read More >

Happy New Year!

We are very excited to launch our new website! Please take a few moments to click around and explore...

Read More >